{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:03:24Z","timestamp":1790096604539,"version":"4.0.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","award":["20180551230"],"award-info":[{"award-number":["20180551230"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5915-7","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T14:03:18Z","timestamp":1563372198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9645-7990","authenticated-orcid":false,"given":"Yunpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"key":"5915_CR1","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.jtho.2016.05.019","volume":"11","author":"M Bersanelli","year":"2016","unstructured":"Bersanelli M, Minari R, Bordi P, et al. L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC. J Thorac Oncol. 2016;11:e121\u20133.","journal-title":"J Thorac Oncol"},{"key":"5915_CR2","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/JTO.0000000000000559","volume":"10","author":"R Rami-Porta","year":"2015","unstructured":"Rami-Porta R, et al. The IASLC lung Cancer staging project. J Thoracic Oncol. 2015;10:990\u20131003.","journal-title":"J Thoracic Oncol"},{"key":"5915_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.lungcan.2015.06.001","volume":"89","author":"L Gong","year":"2015","unstructured":"Gong L, Xiong M, Huang Z, et al. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations. Lung Cancer. 2015;89:268\u201373.","journal-title":"Lung Cancer"},{"key":"5915_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00280-015-2759-y","volume":"75","author":"T Kawamura","year":"2015","unstructured":"Kawamura T, Hata A, Takeshita J, et al. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs. Cancer Chemother Pharmacol. 2015;75:1261\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"key":"5915_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5306\/wjco.v5.i1.19","volume":"5","author":"W Zhu","year":"2014","unstructured":"Zhu W, Zhou L, Qian JQ, et al. Temozolomide for treatment of brain metastases: a review of 21 clinical trials. World J Clin Oncol. 2014;5:19\u201327.","journal-title":"World J Clin Oncol"},{"key":"5915_CR6","first-page":"1753","volume":"9","author":"D Morichika","year":"2016","unstructured":"Morichika D, Kubo T, Gotoda H, et al. Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation. Onco Targets Ther. 2016;9:1753\u20138.","journal-title":"Onco Targets Ther"},{"key":"5915_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/01.wnl.0000223348.42106.97","volume":"67","author":"B Van de Langerijt","year":"2006","unstructured":"Van de Langerijt B, Gijtenbeek JM, de Reus HP, et al. CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology. 2006;67:114\u20139.","journal-title":"Neurology."},{"key":"5915_CR8","first-page":"1313","volume":"3","author":"L Jiang","year":"2016","unstructured":"Jiang L, Li P, Gong Z, et al. Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin. Anticancer Res. 2016;3:1313\u20138.","journal-title":"Anticancer Res"},{"key":"5915_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560\u20132.","journal-title":"Nat Med"},{"key":"5915_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4143\/crt.2018.138","volume":"51","author":"J Lee","year":"2019","unstructured":"Lee J, Shim JH, Park WY, et al. Rare mechanism of acquired resistance to osimertinib in Korean patients with EGFR-mutated non-small cell lung cancer. Cancer Res Treat. 2019;51:408\u201312.","journal-title":"Cancer Res Treat"},{"key":"5915_CR11","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","volume":"24","author":"Z Yang","year":"2018","unstructured":"Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018;24:3097\u2013107.","journal-title":"Clin Cancer Res"},{"key":"5915_CR12","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1039\/C7SC04761D","volume":"9","author":"D Callegari","year":"2018","unstructured":"Callegari D, Ranaghan KE, Woods CJ, et al. L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung ca ncer drug osimertinib. Chem Sci. 2018;9:2740\u20139.","journal-title":"Chem Sci"},{"key":"5915_CR13","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-14-2789","volume":"21","author":"D Ercan","year":"2015","unstructured":"Ercan D, Choi HG, Yun CH, et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res. 2015;21:3913\u201323.","journal-title":"Clin Cancer Res"},{"key":"5915_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtho.2016.11.2231","volume":"12","author":"CC Ho","year":"2017","unstructured":"Ho CC, Liao WY, Lin CA, et al. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J Thorac Oncol. 2017;12:567\u201372.","journal-title":"J Thorac Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5915-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5915-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5915-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T23:05:14Z","timestamp":1594854314000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5915-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5915"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5915-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,17]]},"assertion":[{"value":"3 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s next of kin for publication of this case report and associated images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"702"}}